spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  AMD  

 HSMN NewsFeed - 5 Jan 2023
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Aug 2022
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Mar 2022
LumiThera, Inc. Announces Completion of Diopsys, Inc. Acquisition
Devices Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 11 Nov 2021
LumiThera, Inc. Announces Creation of a Light-based Theranostic Approach to Treat Ocular Disease with Acquisition of Diopsys, Inc.
Devices Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 13 Sep 2021
AbbVie and REGENXBIO Announce Eye Care Collaboration
Biopharmaceuticals Regenerative Medicine Ophthalmology
 HSMN NewsFeed - 7 May 2021
LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema
Devices Ophthalmology
 HSMN NewsFeed - 7 Apr 2021
LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
Devices Ophthalmology
 HSMN NewsFeed - 21 Sep 2020
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 8 Jul 2020
LumiThera Closes Series C Round of Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 18 Feb 2020
LumiThera to Expand Research into Diabetic Retinopathy for Valeda(R) Light Delivery System
Devices Ophthalmology
 HSMN NewsFeed - 13 Jan 2020
LumiThera Closes 2nd Tranche of Series C Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Jan 2020
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 4 Sep 2019
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 13 Aug 2019
FDA Approves EYLEA(R) (aflibercept) Injection Prefilled Syringe
Biopharmaceuticals Drug Delivery Ophthalmology FDA
 HSMN NewsFeed - 29 Nov 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 13 Aug 2018
Regeneron Provides Regulatory Update on EYLEA(R) (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 9 Jul 2018
Oculocare's Alleye(R) Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD
Devices Diagnostics Ophthalmology FDA
 HSMN NewsFeed - 20 Mar 2018
Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Feb 2018
SnoreRx, Now Available at CVS, is First and Only FDA Certified Non-prescription Anti Snoring Treatment
Devices Product Launch
 HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2017
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Nov 2017
Regeneron Provides Update on EYLEA(R) (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 31 Oct 2017
LumiThera Closes Series B Round of Financing
Devices Ophthalmology Venture Capital Personnel
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 11 Jan 2017
FDA Grants VisionCare Inc. Approval to Initiate Clinical Study of the Telescope Implant in Post-Cataract Patients
Devices Ophthalmology FDA
 HSMN NewsFeed - 12 Dec 2016
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista(R) in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Dec 2016
Exonate Closes Successful Funding Round - To Develop Eye Drops Treatment for Wet Age-related Macular Degeneration (Wet AMD)
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 13 Oct 2016
Ocular Therapeutix(TM) and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Oct 2016
FDA Grants Priority Review to Genentech’s Lucentis(R) (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 31 May 2016
Pixium Vision Receives Clinical Trial Approval from UK Regulatory Authority for 150 Electrode IRIS(R)II Bionic Vision System
Devices Ophthalmology Regulatory
 HSMN NewsFeed - 4 May 2016
Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer
Devices Monitoring Ophthalmology Personnel
 HSMN NewsFeed - 2 May 2016
Graybug Vision Announces $44.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 23 Mar 2016
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 11 Jan 2016
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
Biopharmaceuticals Oncology Ophthalmology Venture Capital
 HSMN NewsFeed - 5 Jan 2016
Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 22 Jul 2015
Second Sight Announces First Age-Related Macular Degeneration Patient Receives the Argus II Retinal Prosthesis System as Part of Groundbreaking Study
Devices Ophthalmology
 HSMN NewsFeed - 21 Jul 2015
Ophthotech Announces New Senior Leadership Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel
 HSMN NewsFeed - 3 Mar 2015
Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
Devices Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2015
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 13 Oct 2014
FDA Approves VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older
Devices Ophthalmology FDA
 HSMN NewsFeed - 3 Oct 2014
Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Feb 2014
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2014
Advanced Cell Technology Announces Change in Management
Regenerative Medicine Ophthalmology Personnel
 HSMN NewsFeed - 17 Jan 2014
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
Diagnostics Ophthalmology Licensing
 HSMN NewsFeed - 18 Dec 2013
Regeneron Announces FDA Acceptance of EYLEA(R) (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 12 Dec 2013
Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development
Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Nov 2013
EYLEA(R) (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 12 Nov 2013
Bayer receives approval for Eylea(R) as new drug to treat wet Age-Related Macular Degeneration Patients in Canada
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 19 Sep 2013
Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 6 Aug 2013
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Biopharmaceuticals Drug Delivery Ophthalmology Personnel
 HSMN NewsFeed - 26 Jul 2013
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 4 Apr 2013
New Therapy for Wet AMD Introduced in Switzerland by Oraya(R) Therapeutics and EyeRAD
Devices Ophthalmology
 HSMN NewsFeed - 11 Mar 2013
MacuLogix Raises $3.6 Million in Series A Round
Diagnostics Ophthalmology Venture Capital
 HSMN NewsFeed - 19 Feb 2013
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 1 Aug 2012
Lpath Appoints Daniel L. Kisner, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2012
FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology Endocrinology FDA
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 3 May 2012
Oraya Therapeutics Achieves Successful INTREPID Study Outcomes with a Non-Invasive Radiation Therapy for Wet AMD
Devices Ophthalmology
 HSMN NewsFeed - 2 May 2012
ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells
Regenerative Medicine Ophthalmology
 HSMN NewsFeed - 11 Apr 2012
MacuCLEAR, Inc. To Begin Phase III Study of its Lead Compound for Early-Stage Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 3 Jan 2012
New Study Links Daily Aspirin Use to Increased Risk of Age-Related Macular Degeneration
Biopharmaceuticals Cardiology Ophthalmology
 HSMN NewsFeed - 8 Aug 2011
Acucela Appoints Michelle Carpenter, J.D., RAC, as Senior Vice President, Regulatory Affairs & Development Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Mar 2011
Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 11 Feb 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
Biopharmaceuticals Endocrinology Ophthalmology
 HSMN NewsFeed - 10 Jan 2011
VisionCare Ophthalmic Technologies Closes $31 Million Series E Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Jul 2010
VisionCare Announces FDA Approval for First-Ever Implantable Telescope for End-Stage Macular Degeneration
Devices Ophthalmology FDA
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Jun 2010
TomoTherapy Focuses on Benefits of Adaptive Radiation Therapy at the AAMD 35th Annual Meeting
Devices Oncology
 HSMN NewsFeed - 7 Apr 2010
Oraya Therapeutics Granted European CE Mark for the IRay(TM) Stereotactic Radiotherapy System
Devices Ophthalmology Regulatory
 HSMN NewsFeed - 9 Feb 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Diagnostics Ophthalmology Licensing
 HSMN NewsFeed - 5 Jan 2010
Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD
Devices Ophthalmology
 HSMN NewsFeed - 15 Dec 2009
Ophthotech Raises $30 Million in Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Aug 2009
Oraya Therapeutics Names Jim Taylor as President and Chief Executive Officer
Devices Ophthalmology Personnel
 HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Jul 2009
Oraya Therapeutics Raises $42 Million in Series C Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 7 May 2009
Merck Serono Initiates SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 21 Apr 2009
iScience Interventional, Inc. Closes $20.5 million Series F Financing
Devices Ophthalmology Venture Capital
 HSMN NewsFeed - 10 Mar 2009
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
Diagnostics Ophthalmology
 HSMN NewsFeed - 27 Nov 2008
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 6 Nov 2008
MacuSight Appoints Gerald Wroblewski Vice President of Operations
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 8 Oct 2008
FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression
Devices Neurology FDA
 HSMN NewsFeed - 22 Sep 2008
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2008
Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications - Retinitis Pigmentosa and Dry Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Aug 2008
Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Opthalmology
 HSMN NewsFeed - 9 Jul 2008
Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Jul 2008
Pipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2008
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Apr 2008
FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.
Devices Ophthalmology FDA
 HSMN NewsFeed - 7 Apr 2008
Quark Pharmaceuticals, Inc. Closes $27 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Apr 2008
NeoVista Receives CE Mark Approval to Distribute Wet AMD Device in Europe
Devices Ophthalmology Regulatory
 HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Devices Ophthalmology
 HSMN NewsFeed - 18 Mar 2008
Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
Biopharmaceuticals Venture Capital Ophthalmology
 HSMN NewsFeed - 8 Jan 2008
Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 29 Nov 2007
First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Oct 2007
Optherion, Inc. Completes $37 Million Start Up Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 2 Oct 2007
Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 2 Aug 2007
Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Jul 2007
Pipex Pharmaceuticals Acquires Late-Stage Oral Candidate for Dry Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jun 2007
SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 9 May 2007
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Apr 2007
CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 27 Mar 2007
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2007
Athenagen Announces Name Change to CoMentis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jan 2007
Novadaq Establishes Direct US Sales Team
Devices Cardiology
 HSMN NewsFeed - 3 Jan 2007
Genaera Corporation Terminates EVIZON(TM) Clinical Program and Restructures
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Dec 2006
Sirna Therapeutics Shareholders Approve Acquisition by Merck & Co.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Dec 2006
Merck & Co. and Sirna Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period for the Proposed Acquisition of Sirna by Merck
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Dec 2006
AmerisourceBergen Acquires Access M.D., Expanding Its Specialty Business into Canada
Biopharmaceuticals Distribution Mergers & Acquisitions
 HSMN NewsFeed - 8 Nov 2006
Carl Zeiss Meditec Announces Installation of 6000th Stratus OCT
Devices Ophthalmology
 HSMN NewsFeed - 8 Nov 2006
OcuCure Therapeutics: Developing Novel Eye Drop Treatments for Wet and Dry Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Nov 2006
Novadaq announces CE Mark for OPTTX System
Devices Ophthalmology Regulatory
 HSMN NewsFeed - 30 Oct 2006
Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Oct 2006
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President of Clinical Development
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 23 Oct 2006
OccuLogix and Asahi Kasei Medical Sign Rheofilter'TM' SR Agreement
Devices Ophthalmology Distribution
 HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 16 Oct 2006
Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Biopharmacetuicals Ophthalmology
 HSMN NewsFeed - 4 Oct 2006
New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Sep 2006
Athenagen Raises $50 Million in Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 26 Sep 2006
Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 12 Sep 2006
OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Sep 2006
Novadaq Announces European Distribution Contract with Kodak
Devices Radiology Distribution
 HSMN NewsFeed - 1 Sep 2006
OccuLogix Completes Acquisition of SOLX
Devices Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 23 Aug 2006
New Study of Depressive Symptoms in Parkinson's Disease Patients Shows Positive Results for Mirapex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Aug 2006
Novadaq hires Divisional Vice President of Sales, Cardiac
Devices Personnel
 HSMN NewsFeed - 17 Aug 2006
iCo Therapeutics Appoints Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2006
Sirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 26 Jun 2006
Lumenis Invests in Exclusive, Worldwide License for New Ophthalmic Technology
Devices Ophthalmology Licensing
 HSMN NewsFeed - 2 Jun 2006
Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2006
Acuity Pharmaceuticals Reports Positive Initial Phase II Results for Bevasiranib (Cand5) in Wet AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 May 2006
Novadaq Announces Study Results Presented at the American Heart Association's Quality Conference
Devices Cardiology Radiology
 HSMN NewsFeed - 9 May 2006
Novadaq receives FDA clearance for SPY labeling changes
Devices Surgery Cardiology FDA
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 May 2006
Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2006
Lpath Introduces Ocular Division
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Apr 2006
Novadaq hires Vice President and General Manager of Ophthalmology
Devices Ophthalmology Personnel
 HSMN NewsFeed - 4 Apr 2006
OccuLogix Expands Focus on Age-Related Eye Diseases
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 3 Apr 2006
GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2006
Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Feb 2006
Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 21 Feb 2006
VaxGen and BD to Jointly Evaluate Novel Dermal Injection Technology for Delivery of VaxGen's Anthrax Vaccine
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 2 Feb 2006
OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 2 Feb 2006
European Commission Approves Macugen for Treatment of All Types of Wet Age-Related Macular Degeneration; First Treatment to Target Underlying Disease Process of Wet AMD
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 14 Jan 2006
Preliminary Phase III Data from Head-To-Head Study of Lucentis Shows Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 103

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 103 additional stories matching:
AMD
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.